Afinitor
NICE recommends Novartis’ previously CDF-exclusive kidney cancer treatment
January 13, 2017Medical Communications, Sales and Marketing Afinitor, CDF, NICE, Novartis, everolimus
In a reappraisal decision by NICE, everolimus (Novartis’ Afinitor) has been recommended for the treatment of advanced renal cell carcinoma …
EU approval for Eisai kidney cancer treatment
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Afinitor, Eisai, Kisplyx, Lenvima, everolimus
The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …
NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund
August 18, 2016Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica
NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …
Eisai partners with Novartis in renal cell carcinoma collaboration
June 3, 2016Medical Communications, Sales and Marketing Afinitor, Eisai, Lenvima, Novartis, US, everolimus, lenvatinib mesylate
Eisai (TYO: 4523) has announced that it has entered into a partnership with Novartis Pharmaceuticals to collaborate on commercial and …
Novartis’ Afinitor gets EU approval to treat cancerous gastrointestinal or lung tumors
June 2, 2016Research and Development, Sales and Marketing Afinitor, Cancer, European Commission, Novartis, regulation
Swiss drugmaker Novartis (VTX: NOVN) on Thursday said the European Commission has approved its Afinitor (everolimus) to treat cancerous gastrointestinal …
Afinitor receives EU recommendation to treat rare lung cancer
April 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing Afinitor, Novartis
Novartis has received a recommendation from the Committee for Medicinal Products for Human Use at the European Medicines Agency for …
Novartis drug Afinitor significantly reduces seizures in TSC patients
April 21, 2016Research and Development Afinitor, Novartis, Tuberous Sclerosis Complex, drug, seizure, seizures, tsc
Novartis (SIX: NOVN) has announced the results from a Phase III clinical trial which shows that Afinitor (everolimus) significantly reduced …
FDA approves new indication for Novartis’ Afinitor
February 29, 2016Research and Development, Sales and Marketing Afinitor, Novartis
Novartis’ cancer drug Afinitor (everolimus) has been granted FDA approval in a new indication: for the treatment of adult patients …
Eisai submits new cancer combo to EMA for approval
January 12, 2016Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib
Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …
Study shows Novartis’s Afinitor positively reduces tumors
September 30, 2015Research and Development Afinitor, Novartis
Novartis has announced the results of a Phase III pivotal study, showing Afinitor (everolimus) tablets reduced the risk of progression …
Bristol-Myers Squibb notches kidney cancer first with Opdivo
September 28, 2015Research and Development Afinitor, Bristol-Myers Squibb, Kidney cancer, advanced kidney cancer, everolimus, nivolumab, opdivo, renal cell carcinoma
Bristol-Myers Squibb has announced positive results from a Phase III study comparing Opdivo to Afinitor, the Novartis treatment that is …
NHS backtracks on Cancer Drugs Fund de-listings
March 12, 2015Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus
NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
Exclusive: Novartis drug struck off cancer drugs fund
January 8, 2015Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus
Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …
Mixed bag for Novartis and Astellas in breast cancer
December 15, 2014Research and Development, Sales and Marketing Afinitor, Astellas, Novartis, Xtandi, enzalutamide, everolimus
Preliminary results from a Phase II trial of Astellas’ Xtandi (enzalutamide) show positive benefits for the prostate cancer drug when …
Latest content
